All In Biotech

Drug Trial Radar · NCT02325518

Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Dec 8, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Dec 2014

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
Alcon, a Novartis CompanyIndustry
Sponsor type
Industry
First posted
Dec 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT® Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular hypertension.

Conditions

  • Open-Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspensionDrug

  • Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solutionDrug

  • Subject's habitual PGA monotherapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AMTime frame: Baseline (Day 0), Week 4, Week 8 at 11 AM

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Contact Alcon Japan Ltd. for Trial Locations

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.